{"id":"https://openalex.org/W2145604368","doi":"https://doi.org/10.1200/jco.2005.12.191","title":"Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma\u2014A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network","display_name":"Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma\u2014A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network","publication_year":2005,"publication_date":"2005-01-19","ids":{"openalex":"https://openalex.org/W2145604368","doi":"https://doi.org/10.1200/jco.2005.12.191","mag":"2145604368","pmid":"https://pubmed.ncbi.nlm.nih.gov/15657401"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.12.191","doi":"https://doi.org/10.1200/jco.2005.12.191","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.12.191","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","Consultants in Blood Disorders and Cancer, Louisville, KY","Jackson Oncology Associates, Jackson, MS","Northwest Georgia Oncology Centers, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":[]},{"raw_affiliation_string":"Jackson Oncology Associates, Jackson, MS","institution_ids":[]},{"raw_affiliation_string":"Northwest Georgia Oncology Centers, Marietta, GA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089449243","display_name":"Sharlene Litchy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharlene Litchy","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","Consultants in Blood Disorders and Cancer, Louisville, KY","Jackson Oncology Associates, Jackson, MS","Northwest Georgia Oncology Centers, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":[]},{"raw_affiliation_string":"Jackson Oncology Associates, Jackson, MS","institution_ids":[]},{"raw_affiliation_string":"Northwest Georgia Oncology Centers, Marietta, GA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113783543","display_name":"Don W. Shaffer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Don W. Shaffer","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","Consultants in Blood Disorders and Cancer, Louisville, KY","Jackson Oncology Associates, Jackson, MS","Northwest Georgia Oncology Centers, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":[]},{"raw_affiliation_string":"Jackson Oncology Associates, Jackson, MS","institution_ids":[]},{"raw_affiliation_string":"Northwest Georgia Oncology Centers, Marietta, GA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050692432","display_name":"Van L. Lackey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Van L. Lackey","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","Consultants in Blood Disorders and Cancer, Louisville, KY","Jackson Oncology Associates, Jackson, MS","Northwest Georgia Oncology Centers, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":[]},{"raw_affiliation_string":"Jackson Oncology Associates, Jackson, MS","institution_ids":[]},{"raw_affiliation_string":"Northwest Georgia Oncology Centers, Marietta, GA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089426504","display_name":"Manuel Grimaldi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manuel Grimaldi","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","Consultants in Blood Disorders and Cancer, Louisville, KY","Jackson Oncology Associates, Jackson, MS","Northwest Georgia Oncology Centers, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":[]},{"raw_affiliation_string":"Jackson Oncology Associates, Jackson, MS","institution_ids":[]},{"raw_affiliation_string":"Northwest Georgia Oncology Centers, Marietta, GA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073724595","display_name":"F. Anthony Greco","orcid":"https://orcid.org/0009-0009-4578-0630","observed_orcids":["https://orcid.org/0009-0009-4578-0630"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Anthony Greco","raw_affiliation_strings":["From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","Consultants in Blood Disorders and Cancer, Louisville, KY","Jackson Oncology Associates, Jackson, MS","Northwest Georgia Oncology Centers, Marietta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center and Tennessee Oncology PLLC, Nashville, TN; Northwest Georgia Oncology Centers, Marietta, GA; Jackson Oncology Associates, Jackson, MS; and Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]},{"raw_affiliation_string":"Consultants in Blood Disorders and Cancer, Louisville, KY","institution_ids":[]},{"raw_affiliation_string":"Jackson Oncology Associates, Jackson, MS","institution_ids":[]},{"raw_affiliation_string":"Northwest Georgia Oncology Centers, Marietta, GA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":31.7738,"has_fulltext":false,"cited_by_count":331,"citation_normalized_percentile":{"value":0.99875606,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"23","issue":"6","first_page":"1088","last_page":"1095"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8830000162124634},{"id":"https://openalex.org/keywords/indolent-non-hodgkin-lymphoma","display_name":"indolent non-Hodgkin lymphoma","score":0.9929999709129333},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9440000057220459},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.6290000081062317},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.8619999885559082}],"concepts":[{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.9588915109634399},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.933118462562561},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.7515144348144531},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6186798810958862},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4844939410686493},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4656470715999603},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4598809480667114},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4462599754333496},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42864957451820374},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3765452206134796}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2005.12.191","doi":"https://doi.org/10.1200/jco.2005.12.191","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.12.191","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:15657401","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15657401","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W206701898","https://openalex.org/W1912693401","https://openalex.org/W1915689252","https://openalex.org/W1945251789","https://openalex.org/W1978235999","https://openalex.org/W1979300931","https://openalex.org/W1987684534","https://openalex.org/W2104334201","https://openalex.org/W2110646221","https://openalex.org/W2150000105","https://openalex.org/W2167635913","https://openalex.org/W2264636885","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W2130999625","https://openalex.org/W2052970193","https://openalex.org/W2333157797","https://openalex.org/W1974307608","https://openalex.org/W2542342347","https://openalex.org/W2138053896","https://openalex.org/W2075135318","https://openalex.org/W2058605625","https://openalex.org/W1969589284","https://openalex.org/W3171992547"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"compare":[2],"the":[3,78,91,98,131,150,160,220,226],"benefit":[4,87,156,207,229],"of":[5,49,80,85,93,107,154,205,222,228,238,245],"maintenance":[6,64,132,151,161,171,214],"rituximab":[7,10,65,75,86,95,118,155,202,206,217],"therapy":[8,66],"versus":[9],"re-treatment":[11,76,163,218],"at":[12,71,77,219],"progression":[13],"in":[14,130,149,159,174,181],"patients":[15,32,109,172,192],"with":[16,44,52,200,211,230],"previously":[17],"treated":[18,43],"indolent":[19,39],"non-Hodgkin's":[20,40],"lymphoma.":[21],"PATIENTS":[22],"AND":[23],"METHODS:":[24],"Between":[25],"June":[26],"1998":[27],"and":[28,120,143,162,177,243],"August":[29],"2002,":[30],"114":[31,108],"who":[33,193],"had":[34,110],"received":[35],"previous":[36],"chemotherapy":[37],"for":[38],"lymphoma":[41,81],"were":[42,58,121,147,187],"a":[45],"standard":[46],"4-week":[47,68],"course":[48],"rituximab.":[50],"Patients":[51],"objective":[53,111,195],"response":[54,112,145,196],"or":[55,74,113,197,216],"stable":[56,114,198],"disease":[57,115,199],"randomly":[59,122],"assigned":[60,123],"to":[61,124,252],"receive":[62],"either":[63,212,231],"(standard":[67],"courses":[69],"administered":[70],"6-month":[72],"intervals)":[73],"time":[79,221],"progression.":[82,223],"The":[83],"duration":[84,204],"was":[88,102,128,157],"measured":[89],"from":[90],"date":[92,99],"first":[94],"treatment":[96,101,185,215],"until":[97],"other":[100],"required.":[103],"RESULTS:":[104],"Ninety":[105],"(79%)":[106],"after":[116],"initial":[117],"treatment,":[119],"treatment.":[125],"Progression-free":[126],"survival":[127],"prolonged":[129,210],"group":[133],"(31.3":[134,165],"v":[135,166],"7.4":[136],"months;":[137],"P":[138],"=":[139],".007).":[140],"Final":[141],"overall":[142],"complete":[144,182],"rates":[146],"higher":[148],"group.":[152],"Duration":[153],"similar":[158],"groups":[164],"27.4":[167],"months,":[168],"respectively).":[169],"More":[170],"remain":[173],"continuous":[175],"remission,":[176],"more":[178],"are":[179],"currently":[180],"remission.":[183],"Both":[184],"approaches":[186],"well":[188],"tolerated.":[189],"CONCLUSION:":[190],"In":[191],"have":[194],"single-agent":[201],"therapy,":[203],"is":[208,241,250],"substantially":[209],"scheduled":[213],"At":[224],"present,":[225],"magnitude":[227],"approach":[232],"appears":[233],"similar.":[234],"However,":[235],"additional":[236],"follow-up":[237],"this":[239,255],"trial":[240],"required,":[242],"completion":[244],"phase":[246],"III":[247],"randomized":[248],"trials":[249],"necessary":[251],"definitively":[253],"answer":[254],"question.":[256]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":19},{"year":2012,"cited_by_count":19}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}